Lilly to Market Groundbreaking Alzheimer's Diagnostic Drug

Eli Lilly & Co. (LLY) has gained the green light to market Tauvid which can be used to identify neurofibrillary tangles formed within brain neurons in people with Alzheimer's Disease.  This groundbreaking method using Eli Lilly & Co.'s (LLY) drug is very significant, as the tau tangles previously lacked any way to identify the Alzheimer's characteristic in living individuals.

Alzheimer's is a medical disease of which I have some knowledge.  Second Renaissance Books, the bookstore set up by Ayn Rand herself, sold a book about the condition which I read that was nearly 250 pages.

Eli Lilly & Co. (LLY) has been working on Alzheimer's Disease for a very long time.  Despite this new diagnostic tool, their still remains no medical treatment for Alzheimer's.  However, Lilly's tau-based diagnosis could become widely used.

I googled Alzheimer's population statistics and found that 10% of Americans age 65 and older have Alzheimer's Disease.  And, 32% of those age 85 and older have Alzheimer's.

Eli Lilly's test to alert families about a relative who is beginning to get Alzheimer's Disease may develop a high demand.  And, when one multiplies that demand by the prevalence in the population of America, and the entire World, Eli Lilly & Co.'s (LLY) diagnostic drug could prove lucrative, indeed.

Paul Wharton

Special thanks to Eli Lilly & Co. (LLY) for inventing the fuel of my mind

Covid 19 Profit (x9)

Last Friday, the Eli Lilly & Co. (LLY) partner in the fight against Covid 19, AbCellera Biologics Inc., announced that the two medical companies have expanded their collaboration to go beyond the effort to battle the virus.  AbCellera is unique in their scientific minds, method, and equipment that can be marshaled to discover useful antibodies as a powerful weapon against disease.  But now, not only will Eli Lilly & Co. (LLY) be advancing towards a Covid 19 product, there is a deal for possibly 9 medicines to counter different medical issues that could prove equally lucrative.  Through trying a novel antibody identification approach, Eli Lilly & Co. (LLY) believes it has stumbled upon a wealth of opportunity that can be the mother load of future profits.

Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific officer and president of Lilly Research Laboratories, stated, "AbCellera's capabilities and team are extremely impressive and we are proud of the progress we've made together thus far."

Paul Wharton

Special thanks to Eli Lilly & Co. (LLY) for inventing the fuel of my mind

Lilly's COVID 19 Candidate Fast Tracked

The Eli Lilly & Co. (LLY) drug, Olumiant (also known as baricitinib) has been fast tracked to a final study before use to fight COVID 19.  Lilly's baricitinib, already used to treat rheumatoid arthritis, belongs to a class of weapons against COVID 19 that have the advantage of a safely proven track record in the human body.  President Trump pushed for the first two of these, which he added to the American arsenal.  And, just last week, a Gilead Science (GILD) drug, remdesivir, became the third.  However, Lilly's baricitinib is already in tests to find out if it will be the fourth, and, in fact, could be used as a tandem drug combination with Gilead's medicine.

I am pleased that government drug regulatory departments are, for the most part, getting out of the way.  After all, it isn't just the non-paying, drug-injected welfare cases that may suffer if an under-tested drug has harmful side effects.  Those who have to wait and die before the government lets a pharmaceutical company sell it's product pay a big price too.

Paul Wharton

Special thanks to Eli Lilly & Co. (LLY) for inventing the fuel of my mind

Lilly Battles Virus With Another Deal

Eli Lilly & Co. (LLY) has announced yet another collaboration with a biotech company to battle COVID 19.  This time it is with Junshi Biosciences.

The two companies will strive to co-develop therapeutic antibodies for treatment and prevention of COVID 19.

As President Trump deregulates biotechnology and pharmaceuticals in response to the greater and greater realization that the economy will only recover in the short run if the long run medical solution is no longer in the "long run", more and more companies are diverging resources and effort towards the promise of a Capitalism friendly business environment when this crisis is over with.

Paul Wharton

Special thanks to Eli Lilly & Co. (LLY) for inventing the fuel of my mind